| abstract |
A description is given of a recombinant vaccine that comprises a sero type 9 avian adenovirus vector (FAdV-9) with the insertion of at least one exogenous nucleotide sequence that codes for at least one antigen of a disease of interest and that replaces the non-essential region of the adenovirus genome, and a vehicle, adjuvant and/or excipient that is pharmaceutically acceptable, wherein the at least one exogenous nucleotide sequence that codes for at least one antigen of a disease of interest and that replaces the non-essential region of the adenovirus genome is located between nucleotides 491-2782. The vector of this vaccine is stable for production on an industrial scale. Likewise, even when this vaccine is administered in combination with a vaccine against Marek's disease, the two vaccines produce an adequate immune response that is unaffected by interference between them. Similarly, the efficacy of the recombinant vaccine is unaffected by maternal antibodies and is capable of inducing a protective response that is both early and long-lasting, even with a single application. |